Cart
×
Google’s Project Euphonia
Get Involved with Project Euphonia Help future generations of people living with motor speech impairments. Automated speech recognition, which powers voice-activated technology such as the Google Assistant, are more common […]
Dyne Therapeutics Series B financing
CureDuchenne congratulates the incredible Dyne Therapeutics team, who recently announced closing $115M in equity financing to develop transformational therapies for patients with serious muscle diseases. We share this news in […]
Nationwide Children’s Hospital Begins New First-in-Human Clinical Study for DMD Using a Novel Gene Therapy Approach
CureDuchenne is very proud that Dr. Kevin Flanigan, at Nationwide Children’s Hospital, has treated two patients with gene therapy that carry the Duplication 2 mutation. CureDuchenne funded Dr. Flanigan’s very […]
EveryLife Survey – What’s the cost of rare disease to YOU?
Take this Survey by July 19! CureDuchenne is supporting the EveryLife Foundation for Rare Diseases in their effort to conduct a survey of families living with rare diseases. This survey […]
PFIZER’S NEW PHASE 1B RESULTS OF GENE THERAPY IN AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) SUPPORT ADVANCEMENT INTO PIVOTAL PHASE 3 STUDY
Friday, May 15, 2020 – 8:00amEDT Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy […]
Updates from ASGCT 2020
CureDuchenne Ventures’ latest investment in Myosana Therapeutics
CureDuchenne Ventures is happy to announce its latest investment in Myosana Therapeutics, a new biotech company based in Seattle, WA. Myosana is aiming to develop next-generation gene therapy for Duchenne muscular dystrophy and other neuromuscular […]
Letter to the Community – Myosana Therapeutics
Dear Duchenne Community, I’m truly thrilled about our investment in a new biotech company called Myosana Therapeutics. Myosana aims to develop next-generation gene therapy for Duchenne muscular dystrophy and neuromuscular diseases. Because of this investment, the team is now positioned to conduct […]